Category: pSivida Corp.Syndicate content

pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review

December 19, 2013 by Arezu Sarvestani

pSivida's shares spike 35% on news that the company's Iluvien eye drug/device combination will skip ahead to final FDA review, bypassing the advisory panel process.

pSivida soars as copmany skips FDA avisory panel on review path for Iluvien

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UK regulators OK pSivida's Iluvien

December 4, 2013 by Chris Walker

The UK's National Institute for Health & Care Excellence OK's pSivida's Iluvien drug/device combo for cataract surgery patients with chronic diabetic macular edema.

pSivida's Iluvien backed by UK National Health Service

pSivida (NSDQ:PSDV) said the UK's National Institute for Health & Care Excellence approved its Iluvien drug/device combination.

The approval is for cataract surgery patients who don't respond to standard treatment for diabetic macular edema, according to a press release.

Third time's no charm for pSivida, Alimera as FDA again denies Iluvien eye treatment

October 18, 2013 by Arezu Sarvestani

Wall Street flees from pSivida and licensee Alimera Sciences as the FDA hands down its 3rd rejection for the Iluvien vision repair implant.

Third time's no charm for pSivida as FDA again denies Iluvien eye treatment

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Alimera's Iluvien vision repair implant wins national insurance coverage in France

July 25, 2013 by Sony Salzman

France grants Alimera's Iluvien vision repair implant national insurance coverage, with up to 100% reimbursement for certain patients.

pSivida
Alimera Sciences

The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.

Gamma Medica closes $18M Series A round | Wall Street Beat

July 19, 2013 by Brad Perriello

Gamma Medica says it's closed an $18 million Series A funding round for its molecular breast imaging device.

MassDevice.com Wall Street Beat

Gamma Medica said it's closed a $16 million Series A round from Psilos Group Managers.

The Northridge, Calif.-based company said it plans to use the cash to expand the commercial footprint of its LumaGen molecular breast imaging device and the LumaGuide biopsy model.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

pSivida launches Phase III study of its micro-sized eye implant

July 5, 2013 by Sony Salzman

pSivida kicks off enrollment in the 1st of 2 planned efficacy trials for a drug/device combo to treat eye inflammation and prevent vision loss.

pSivida launches Phase III of its drug/device combo for vision loss r

pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.

pSivida gains big on buyout rumor

June 19, 2013 by Brad Perriello

A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology company's shares up nearly 4% today to a 52-week high.

pSivida gains big on buyout rumor

Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it's ripe for an acquisition this year.

PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob's Stocks" published the rumor yesterday.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp